Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Sosnowiec – page 35

1 193 clinical trials in Sosnowiec, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Sosnowiec at a glance
1 193
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 193 trials in Sosnowiec

Open in trial search

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not yet recruiting

Evaluating Datopotamab Deruxtecan with drug combination in adults with TROP2‑positive non‑small cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Myasthenia gravis

Not yet recruiting

Phase 2 Study to Evaluate Efficacy and Safety of Ublituximab Maintenance after Induction with Efgartigimod Alfa in Adults with Myasthenia Gravis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Tg Therapeutics Inc.

Parkinson's disease

Not yet recruiting

Efficacy and Safety of Carbidopa/Levodopa (CP-012B) in Participants with Parkinson’s Disease with Early Morning OFF Episodes

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Carbidopa
  • Sponsor:Contera Pharma A/S

Dermatitis atopic

Not yet recruiting

Efficacy of comekibart Injection in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Hunan Mabgeek Biotech Co. Ltd.

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged ≥12 Years with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Randomized Placebo‑Controlled Trial of Cenerimod for Efficacy and Safety in Adults with Systemic Lupus Erythematosus and Active Lupus Nephritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Sosnowiec

What the registry says about research in the country

01 Respiratory Diseases

Innovative clinical trials focusing on chronic obstructive pulmonary disease (COPD) and asthma management, testing new inhaler formulations and investigating treatments for respiratory conditions including respiratory syncytial virus (RSV).

  • COPD Treatment Optimization
  • Asthma Management
  • Respiratory Infections

Studies include evaluation of triple therapy combinations and novel propellant technologies for improved drug delivery.

02 Dermatological Conditions

Research examining treatments for various skin conditions, including atopic dermatitis, psoriasis, and hidradenitis suppurativa, with particular focus on innovative biological therapies.

  • Inflammatory Skin Diseases
  • Pediatric Dermatology
  • Chronic Skin Conditions

Clinical investigations include both adult and pediatric populations, testing new targeted therapies.

03 Gastrointestinal Disorders

Studies evaluating treatments for inflammatory bowel conditions, particularly Crohn's disease and ulcerative colitis, testing novel therapeutic approaches for disease management.

  • Inflammatory Bowel Disease
  • Long-term Disease Management
  • Novel Therapeutic Approaches

Focus on both induction and maintenance therapy for moderate to severe disease states.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.